DERM
Journey Medical Corporation
There isn't enough reported data to score DERM yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DERM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Strong |
DERM's revenue and balance sheet are currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DERM PE Valuation
DERM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DERM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
DERM has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DERM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.30 | — |
| Q3 2026 | -$0.18 | +$0.15 |
| Q2 2026 | -$0.22 | +$0.14 |
| Q1 2026 | -$0.37 | $0.00 |
| Q4 2025 | -$0.47 | +$0.25 |
| Q3 2023 | -$0.84 | +$2.61 |
| Q2 2023 | -$2.21 | +$1.83 |
| Q1 2023 | -$2.18 | +$2.73 |
| Q4 2022 | -$1.69 | +$3.11 |
DERM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DERM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +7.6% |
| Q2 2026 | $18.5M | +23% |
| Q1 2026 | $16M | +21% |
| Q4 2025 | $16.1M | +18% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $15M | +1% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $13.6M | -11% |
DERM's revenue is recovering but still below its 2023 peak: $19M last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.8% | +5.9 points |
| Q2 2026 | 2.5% | +22 points |
| Q1 2026 | -9.3% | +16 points |
| Q4 2025 | -2.8% | -19 points |
| Q3 2025 | -8.7% | +11 points |
| Q2 2025 | -19% | +0.5 points |
| Q1 2025 | -25% | +52 points |
| Q4 2024 | 16% | +30 points |
DERM has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DERM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DERM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | -$1.1M |
| Q2 2026 | -$1.7M | -$792K |
| Q1 2026 | $2.9M | +$5.7M |
| Q3 2023 | $18.7M | +$26M |
| Q2 2023 | $4M | +$7.3M |
| Q1 2023 | -$6M | -774% |
| Q2 2022 | -$3.3M | +$4.1M |
| Q1 2022 | $884K | -35% |
DERM has burned cash in most quarters: −$5M over the past year, against −$2M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DERM in the latest year-over-year cash flow comparison.
DERM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +575K shares |
| 1 year | +12% | +3.1M shares |
| 3 years | +33% | +7M shares |
| 5 years | +206% | +18.9M shares |
| Available history | -48% | -26.4M shares |
DERM has 28M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q3 2019 | $163,999 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DERM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DERM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | 0.2x | Very low |
DERM has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DERM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 7.6 | Oversold |
DERM's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DERM PE vs Healthcare Sector
DERM has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DERM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.38 | 18% below |
| 20 week MA | $6.38 | 31% below |
| 50 week MA | $6.65 | 34% below |
| 100 week MA | $6.59 | 33% below |
| 200 week MA | $5.14 | 15% below |
DERM is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DERM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.50 | $5.70 | -40% |
| 2022 | $5.70 | $1.18 | -79% |
| 2023 | $1.18 | $5.76 | +388% |
| 2024 | $5.76 | $4.17 | -28% |
| 2025 | $4.17 | $7.92 | +90% |
| 2026 YTD | $7.92 | $4.39 | -45% |
DERM's yearly returns have swung widely, from +388% in 2023 to −79% in 2022. It's down 45% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over DERM on returns for 2026, with the stronger performance.